Osteoporosis is a condition in which bones lose strength and become more likely to fracture. A central DXA scan measures bone mineral density and helps diagnose or classify osteoporosis, but it does not explain why bone loss occurred. Osteoporosis blood tests can look for vitamin D deficiency, abnormal calcium regulation, thyroid or parathyroid disease, kidney or liver problems, malabsorption, inflammation, and hormone changes that may be contributing to weak bones.
That distinction matters: DXA finds low bone density; laboratory testing investigates potentially reversible or treatable contributors. Blood tests do not diagnose osteoporosis by themselves, and no single “bone panel” is right for everyone. Results should be interpreted with age, sex, menstrual or reproductive status, fracture history, medications, nutrition, kidney function, and imaging.
Ulta Lab Tests offers direct access to many of the laboratory tests discussed below. Testing is educational and should complement—not replace—evaluation by a qualified healthcare professional.
Medical disclaimer: This article is for general education and is not medical advice. Laboratory results cannot diagnose osteoporosis or determine treatment on their own. Seek professional care for symptoms, fractures, abnormal calcium results, or medication decisions.
Bone is living tissue. Throughout life, older bone is removed and new bone is formed. Osteoporosis develops when bone breakdown outpaces bone formation enough to reduce bone strength. Age, menopause, and genetics are major influences, but they are not the whole story.
Primary osteoporosis is mainly associated with aging and postmenopausal hormonal change. Secondary osteoporosis is bone loss caused or worsened by another condition, nutrient problem, medication, or prolonged low energy availability. Both can occur at the same time. Finding a secondary contributor can change the clinical plan, particularly when bone loss is early, severe, rapid, or unexpected.
For a broader overview, see Ulta Lab Tests’ guide to osteoporosis symptoms and bone density tests.
A central dual-energy X-ray absorptiometry (DXA) scan typically measures the hip and lumbar spine. In postmenopausal women and men age 50 or older, T-scores are generally interpreted as follows:
| T-score | Usual classification |
|---|---|
| −1.0 or higher | Normal bone density |
| Between −1.0 and −2.5 | Low bone mass, often called osteopenia |
| −2.5 or lower | Osteoporosis |
In premenopausal women, men younger than 50, and children, clinicians generally use Z-scores rather than applying the older-adult T-score categories. A Z-score of −2.0 or lower is described as “below the expected range for age,” but bone density alone is not enough to diagnose osteoporosis in younger adults. The International Society for Clinical Densitometry’s 2023 positions provide the current technical framework.
The U.S. Preventive Services Task Force recommends osteoporosis screening for women age 65 and older and for postmenopausal women younger than 65 who have at least one risk factor and are found to be at increased fracture risk using a clinical risk tool. The evidence remains insufficient for the Task Force to recommend for or against routine screening in men. Individual circumstances can still justify evaluation.
Secondary causes deserve particular attention when the timing or severity of bone loss does not fit the expected pattern.
| Clinical clue | Possible contributor to discuss | Why it matters |
|---|---|---|
| Fracture after a minor fall or routine movement | Osteoporosis, vitamin D deficiency, abnormal calcium regulation | A fragility fracture may be the first sign of weak bone |
| Bone loss at a young age or Z-score at or below −2.0 | Hormone deficiency, celiac disease, genetic or metabolic disorder, low energy availability | Age-related bone loss alone is less likely to explain the finding |
| Kidney stones, high calcium, constipation, or recurrent thirst | Parathyroid or other calcium-regulation disorder | Calcium and parathyroid hormone must be interpreted together |
| Chronic diarrhea, bloating, low weight, or iron deficiency | Celiac disease or other malabsorption | Poor absorption can limit calcium, vitamin D, and protein availability |
| Irregular or absent periods, infertility, low libido, or hot flashes | Low estrogen or another reproductive hormone disturbance | Sex hormones help maintain bone remodeling balance |
| Low libido, reduced shaving frequency, or loss of muscle in men | Testosterone deficiency or pituitary disorder | Low androgen exposure can accelerate bone loss |
| Restrictive eating, heavy training, or low energy availability | Relative Energy Deficiency in Sport (REDs) or undernutrition | Bone formation and reproductive hormones may be suppressed |
| Long-term glucocorticoid use or other bone-affecting medication | Medication-related bone loss | Risk may rise before symptoms appear |
| Unexpected bone loss despite treatment | Poor absorption, adherence issue, untreated secondary cause, or treatment failure | The clinical plan may need reassessment |
Sudden severe back pain, new loss of height, inability to bear weight after a fall, or symptoms suggesting a hip or spine fracture require prompt medical evaluation. Markedly high or low calcium can also require urgent assessment, especially with confusion, weakness, vomiting, dehydration, or abnormal heart rhythm symptoms.
Laboratory testing can help a clinician:
Laboratory testing cannot directly measure bone density, prove that a fracture was caused by osteoporosis, or predict fracture risk in isolation. Even “normal” results do not erase a low DXA result or fragility-fracture history.
The best evaluation is layered. A clinician may begin with a core set and add targeted tests only when history, examination, imaging, or initial results point in a particular direction.
| Test | What it measures | Why it may matter for bone health | Broad pattern that may prompt follow-up | Important limitation |
|---|---|---|---|---|
| Complete Blood Count with Differential and Platelets | Red cells, white cells, hemoglobin, and platelets | Can reveal anemia or other blood-cell abnormalities associated with undernutrition, chronic illness, or marrow disorders | Low hemoglobin or unexpected cell-count changes | Nonspecific; it does not identify the cause of anemia or diagnose bone loss |
| Comprehensive Metabolic Panel | Total calcium, albumin, kidney and liver markers, glucose, proteins, and electrolytes | Screens several organ and mineral pathways relevant to bone and treatment safety | High or low calcium, reduced kidney function, low albumin, or abnormal liver markers | Total calcium is influenced by albumin; normal serum calcium does not rule out osteoporosis |
| Vitamin D, 25-Hydroxy, Total | The main circulating marker used to assess vitamin D status | Vitamin D supports calcium absorption and normal mineralization | A low result may contribute to secondary hyperparathyroidism or poor mineralization | The target range depends on clinical context; more is not always better |
| Phosphate as Phosphorus and Magnesium | Minerals involved in bone and parathyroid physiology | Abnormalities may accompany malnutrition, kidney disease, gastrointestinal loss, or endocrine disorders | Persistently high or low values, especially with abnormal calcium or kidney markers | Serum levels can change with diet, timing, medicines, and acute illness |
| PTH, Intact with Ionized Calcium | Parathyroid hormone plus biologically active calcium | Helps distinguish parathyroid-driven calcium problems from compensatory responses | High calcium with non-suppressed PTH or low vitamin D with elevated PTH | Must be interpreted with vitamin D, kidney function, phosphorus, medicines, and repeat testing when appropriate |
| TSH and Free T4 | Pituitary thyroid signal and circulating free thyroxine | Excess thyroid hormone—endogenous or from over-replacement—can accelerate bone turnover | Suppressed TSH with elevated Free T4, or another discordant pattern | Illness, pregnancy, supplements, and medicines can affect results |
| Celiac Disease Comprehensive Panel | Celiac-associated antibodies with immunoglobulin context | Celiac disease may reduce absorption even without prominent digestive symptoms | Positive or equivocal antibodies that need clinical confirmation | Starting a gluten-free diet before testing can reduce antibody levels and make interpretation harder |
| Ferritin, Iron and Total Iron Binding Capacity Panel | Iron storage and transport markers | Iron deficiency may be a clue to low intake, blood loss, or malabsorption | Low ferritin or low iron availability | Ferritin can rise with inflammation and may not reflect usable iron in every setting |
| Vitamin B12 and Folate Panel | Two nutrients needed for blood and neurologic health | Deficiency can support a broader picture of poor intake or malabsorption and can increase fall risk through neurologic effects | Low or borderline values with compatible symptoms or blood-count changes | Borderline B12 may require additional evaluation; these results do not measure bone density |
| FSH and LH plus Estradiol | Reproductive signaling and estrogen exposure | Useful in selected women with early menopause, absent periods, infertility, or suspected hypothalamic suppression | Low estradiol with an FSH/LH pattern suggesting ovarian or central dysfunction | Timing, hormonal contraception, pregnancy, and menopausal status strongly affect interpretation |
| Testosterone, Total and Free, and Sex Hormone Binding Globulin | Total and estimated free testosterone with its main binding protein | Selected men with symptoms or early bone loss may need evaluation for androgen deficiency | Repeatedly low morning testosterone with compatible symptoms | Diagnosis generally requires properly timed repeat testing and clinical assessment |
| C-Reactive Protein and Sed Rate | Nonspecific markers of inflammation | Persistent inflammation can accompany disorders that increase bone loss | Elevated results supported by symptoms or other findings | Neither test identifies the source of inflammation or diagnoses osteoporosis |
| Hemoglobin A1c and Glucose Panel | Average recent glucose exposure and current blood glucose | Diabetes and metabolic disease can affect bone quality, falls, and treatment planning | Results in a prediabetes or diabetes range that need clinical confirmation | Bone density may underestimate fracture risk in some people with type 2 diabetes |
| Protein Electrophoresis, Serum and Kappa/Lambda Light Chains, Free, with Ratio | Distribution of blood proteins and free light chains | Reserved for selected people with anemia, bone pain, kidney problems, high calcium, or suspicious imaging | A monoclonal or otherwise abnormal pattern | Not a routine screen for everyone; abnormal results need specialist interpretation |
| Collagen Type I C-Telopeptide, Procollagen Type I Intact N-Terminal Propeptide, and Alkaline Phosphatase, Bone Specific | Markers of bone resorption or formation | May help establish turnover and monitor response or adherence in selected treatment plans | A meaningful change from a properly collected baseline | Not diagnostic; timing, fasting, recent fracture, kidney function, and biologic variation affect results |
Start with the clinical question: Was there a low-trauma fracture? What does the central DXA show? Is there meaningful height loss or vertebral compression? A clinician may combine these findings with age, falls, family history, smoking, alcohol exposure, glucocorticoid use, and a validated fracture-risk tool.
A common starting point includes a Complete Blood Count with Differential and Platelets, Comprehensive Metabolic Panel, Vitamin D, 25-Hydroxy, Total, Phosphate as Phosphorus, and thyroid testing such as TSH and Free T4. A provider may add PTH, Intact with Ionized Calcium when calcium, vitamin D, kidney function, stone history, or symptoms raise concern.
Repeat the abnormal test only when the result could change care and at an interval appropriate to the condition or treatment. DXA is repeated on a clinical schedule rather than every time blood is drawn. When bone turnover markers are used, consistent timing, fasting status, laboratory method, and distance from a recent fracture improve comparability.
Single results rarely tell the whole story. Patterns are more informative:
Use the reference interval printed by the performing laboratory. “Optimal” targets promoted online may not apply to your age, diagnosis, pregnancy status, kidney function, or treatment. Trends are most useful when collection conditions and laboratory methods are comparable.
Ulta Lab Tests provides access to individual tests and grouped options such as the Bone Essentials Panel and Bone Plus Comprehensive Panel. Panel contents can change, so compare the current included biomarkers with the plan recommended by your healthcare professional rather than assuming a panel covers every possible cause.
You can also browse bone and joint lab tests, vitamin and mineral tests, thyroid lab tests, kidney function tests, digestive system tests, hormone tests, and inflammation tests.
Availability, collection requirements, and state restrictions may vary. Direct-access testing can make useful data easier to obtain, but it does not replace DXA, fracture assessment, a physical examination, or professional interpretation.
No. Osteoporosis is diagnosed or classified using bone density imaging, fracture history, and clinical context. A central DXA scan is the standard way to measure bone mineral density. Blood tests investigate contributors such as vitamin D deficiency, abnormal parathyroid or thyroid function, kidney disease, malabsorption, and hormone problems. Normal blood results do not cancel a low DXA result or fragility fracture.
Common secondary contributors include vitamin D deficiency, overactive parathyroid or thyroid pathways, chronic kidney or liver disease, celiac disease and other malabsorption, low estrogen or testosterone, chronic inflammation, undernutrition, prolonged low energy availability, and long-term glucocorticoid exposure. The likely causes differ by age, sex, symptoms, medicines, and fracture pattern, so testing should be individualized.
Yes. The body tightly regulates blood calcium, drawing on bone when necessary. As a result, serum calcium can remain normal even while bone density falls. Calcium also changes with albumin, kidney function, parathyroid hormone, vitamin D, medicines, and hydration. A calcium result is one part of a mineral evaluation—not a screening test that rules osteoporosis in or out.
Many clinicians begin with a blood count, metabolic panel, 25-hydroxy vitamin D, phosphorus, and thyroid assessment, then add parathyroid testing when appropriate. The exact baseline varies with guidelines and the individual. Reproductive hormones, celiac antibodies, nutritional markers, inflammation markers, and blood-protein studies are generally more selective and should be driven by history or initial abnormalities.
Vitamin D helps the intestine absorb calcium and supports normal bone mineralization. Low vitamin D can trigger a compensatory rise in parathyroid hormone and may worsen weakness or falls. However, vitamin D is only one contributor to bone health. The appropriate target and need for supplementation depend on the individual, and excessive intake can be harmful.
Excess thyroid hormone can speed bone turnover, including when thyroid replacement is too high. Parathyroid hormone regulates calcium and phosphorus; persistent excess can increase bone resorption. Clinicians interpret thyroid results together and evaluate PTH alongside calcium, vitamin D, phosphorus, magnesium, kidney function, medicines, and symptoms. An abnormal value alone does not establish the final diagnosis.
Yes. Celiac disease can impair nutrient absorption and sometimes presents with iron deficiency, low weight, fatigue, or low bone density rather than obvious diarrhea. Antibody testing can help identify who needs further evaluation. Because reducing gluten may lower antibody levels, do not start a gluten-free diet before testing without discussing the timing and diagnostic plan with a clinician.
They often deserve a careful secondary-cause evaluation when bone loss or a fragility fracture occurs because routine age-related explanations may be less convincing. In younger adults, clinicians usually emphasize Z-scores, fracture history, medications, nutrition, reproductive function, chronic disease, and genetic clues. Hormone testing is targeted to symptoms and must be interpreted using age- and sex-appropriate methods.
There is no universal schedule. Repeat testing depends on what was abnormal, whether treatment or supplementation began, kidney function, symptoms, and whether the result will change care. Some values are repeated after correction; stable normal tests may not need frequent rechecking. DXA and blood tests also follow different timelines. Your clinician should define the purpose and timing of each repeat.
They are bone turnover markers. CTX reflects bone resorption, while P1NP and bone-specific alkaline phosphatase reflect aspects of bone formation. In selected patients, they can help assess baseline turnover or treatment response. They do not diagnose osteoporosis, and results vary with collection time, food intake, recent fracture, kidney function, and laboratory method, so standardized collection is important.
Seek prompt evaluation after a low-impact fall with inability to stand or bear weight, sudden severe back pain after minimal strain, new weakness or numbness, or suspected hip or spine fracture. Markedly abnormal calcium accompanied by confusion, vomiting, severe weakness, dehydration, or rhythm symptoms also needs urgent assessment. Routine low bone density without acute symptoms still warrants timely follow-up, but not usually emergency care.
Osteoporosis is more than a number on a DXA report. Bone loss can reflect aging and menopause, but it can also be amplified by nutrient deficiency, abnormal calcium regulation, thyroid or parathyroid disease, kidney dysfunction, celiac disease, low sex hormones, inflammation, undernutrition, or medication exposure. A focused laboratory evaluation can help reveal those contributors and establish safer treatment baselines.
The most useful strategy is coordinated: confirm bone status, assess fracture risk, choose laboratory tests from the clinical clues, correct identified problems, and monitor only what can change care. If you order tests directly, share the complete results with a qualified healthcare professional and do not make medication changes on your own.
Osteoporosis is a loss of bone strength that raises fracture risk and is usually assessed with central DXA imaging. Osteoporosis blood tests do not diagnose the condition; they help identify secondary contributors and treatment-safety issues that imaging cannot explain.
Related labs: blood count, metabolic panel, 25-hydroxy vitamin D, phosphorus, magnesium, PTH with ionized calcium, TSH and Free T4, celiac antibodies, iron markers, B12/folate, reproductive hormones, inflammation markers, selected protein studies, CTX, P1NP, and bone-specific alkaline phosphatase.
Ulta Lab Tests provides direct access to many individual and grouped bone-health tests, with availability and collection requirements varying by location.
Disclaimer: Educational information only; laboratory testing cannot diagnose osteoporosis or replace professional medical evaluation.
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
